CORDIS
EU research results

CORDIS

English EN

ITCC Pediatric Preclinical POC Platform – Sofia ref.: 116064

Project information

Grant agreement ID: 116064

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 16 562 831,75

  • EU contribution

    € 7 370 000

Coordinated by:

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Germany

Objective

Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant solid tumors, usually after very intensive first-line therapy, curative treatment options are scarce. Preclinical drug testing to identify promising treatment options that match the molecular make-up of the tumor is hampered by the facts that i) molecular genetic data on pediatric solid tumors from relapsed patients and thus our understanding of tumor evolution and therapy resistance are very limited to date and ii) for many of the high-risk entities no appropriate and molecularly well characterized patient-derived models and/or genetic mouse models are currently available. Thus, quality-assured upfront preclinical testing of novel molecularly targeted compounds in a (saturated) repertoire of well-characterized models will establish the basis to increase therapeutic successes of these drugs in children with solid malignancies. Since these tumors are overall genetically much less complex than their adult counterparts, it is anticipated that it will be easier to identify powerful predictive biomarkers to allow for accurate matching of targets and drugs.

To address this high, as yet unmet clinical need, we have formed the ITCC-P4 consortium consisting of academic and commercial partners from 8 European countries and covering the full spectrum of qualifications needed for quality-assured preclinical drug development including expertise in patient derived models, histopathology, in vivo pharmacology, bioinformatics and data management, centralized testing capabilities, medical expertise regarding the entities in question, regulatory knowledge, and project management of large consortia. With this consortium in a public-private partnership with the participating pharma companies we strongly believe to be ideally positioned to greatly expedite the development of more precise and efficacious drugs for children with malignant solid tumors

Coordinator

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Address

Im Neuenheimer Feld 280
69120 Heidelberg

Germany

Activity type

Research Organisations

EU Contribution

€ 2 995 864

Participants (20)

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

EU Contribution

€ 566 750

INNOVATIVE THERAPIES FOR CHILDREN WITH CANCER ASSOCIATION

France

EU Contribution

€ 107 538

INSTITUT GUSTAVE ROUSSY

France

EU Contribution

€ 280 912

ALLEANZA CONTRO IL CANCRO

Italy

EU Contribution

€ 133 776

UNIVERSITAT ZURICH

Switzerland

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 131 075

FUNDACIO SANT JOAN DE DEU

Spain

EU Contribution

€ 129 050

EXPERIMENTELLE PHARMAKOLOGIE UND ONKOLOGIE BERLIN-BUCH GMBH

Germany

EU Contribution

€ 563 425

ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM

Netherlands

EU Contribution

€ 380 300

XENTECH SAS

France

EU Contribution

€ 563 425

ST. ANNA KINDERKREBSFORSCHUNG

Austria

EU Contribution

€ 163 285

INSTITUT CURIE

France

EU Contribution

€ 214 038

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 352 562

PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV

Netherlands

EU Contribution

€ 788 000

Eli Lilly and Company Limited

United Kingdom

F. HOFFMANN-LA ROCHE AG

Switzerland

PFIZER LIMITED

United Kingdom

BAYER AKTIENGESELLSCHAFT

Germany

PHARMAMAR, S.A.

Spain

CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH

Germany

Project information

Grant agreement ID: 116064

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2021

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 16 562 831,75

  • EU contribution

    € 7 370 000

Coordinated by:

DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG

Germany